Targacept, Inc. (Targacept) is a biopharmaceutical company engaged in the design, discovery, and development of neuronal nicotinic receptor (NNR) therapeutics for the treatment of diseases and disorders of the central nervous system. The company currently focuses on developing a robust portfolio of multiple clinical-stage product candidates, as well as preclinical programs, with significant medical need and commercial potential. The company is headquartered in North Carolina, the US.The company reported revenues of (U.S. Dollars) USD 20.09 million during the fiscal year ended December 2008, an increase of 73.52% over 2007. The operating loss of the company was USD 28.14 million during the fiscal year 2008, as compared to an operating loss of USD 31.77 million during 2007. The net loss of the company was USD 25.66 million during the fiscal year 2008, as compared to a net loss of USD 28.07 million during 2007.